Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia

Overview of attention for article published in Journal of Clinical Oncology, March 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

news: 2 news outlets
twitter: 3 X users

facebook: 1 Facebook page

Readers on

mendeley: 65 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 154,756 followers.

@calliecoombsmd @Berninini @DanielleHammo20 Agree with @calliecoombsmd would not make much of this 30 patient retrospective analysis. Median OS of CPX in 60-75 year olds is 9.5 months and no reason to think outcomes would be WORSE in younger pts. Median…

Amonafide Plus Cytarabine Versus Daunorubicin Plus Cytarabine in Secondary Acute Myeloid Leukemia http://t.co/O0dvylXWRV #JCO #leusm

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.